Laurus Labs Stock Hits Record Highs After 5-Month Consolidation
Stock Radar: Laurus Labs stock breaks out of 5-month consolidation to hit fresh record highs; time to buy?
The Economic Times
Image: The Economic Times
Laurus Labs Ltd, a pharmaceutical company, has broken out of a 5-month consolidation period, reaching record highs in May. Analysts suggest short-term traders consider buying the stock, targeting ₹1,300 (approximately $15.90 USD) in the coming weeks.
- 01Laurus Labs stock has reached new record highs after a period of consolidation.
- 02Experts recommend buying the stock for a target price of ₹1,300.
- 03The stock previously peaked at ₹1,140 in January 2026.
- 04Support was found above the 200-day moving average.
- 05Market momentum has shifted positively for Laurus Labs.
Advertisement
In-Article Ad
Laurus Labs Ltd, a key player in the pharmaceutical industry, has successfully broken out of a 5-month consolidation phase, achieving record highs in May. The stock, which previously peaked at ₹1,140 in January 2026, has shown renewed strength after finding support above the 200-day moving average. Analysts are optimistic, suggesting that short-term traders should consider purchasing the stock with a target of ₹1,300 (approximately $15.90 USD) in the upcoming weeks. This breakout indicates a positive shift in market momentum for Laurus Labs, making it an attractive option for investors looking for growth opportunities.
Advertisement
In-Article Ad
Investors in Laurus Labs may see potential gains as the stock targets ₹1,300, which could influence trading decisions and market sentiment.
Advertisement
In-Article Ad
Reader Poll
Are you considering investing in Laurus Labs stock?
Connecting to poll...
Read the original article
Visit the source for the complete story.